A Phase II, randomized, controlled, double blind study to evaluate the haemostatic efficacy and safety of TT-173 applied in the donor site of patients undergoing skin graft.

Trial Profile

A Phase II, randomized, controlled, double blind study to evaluate the haemostatic efficacy and safety of TT-173 applied in the donor site of patients undergoing skin graft.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2016

At a glance

  • Drugs TT 173 (Primary)
  • Indications Blood coagulation disorders; Perioperative haemorrhage
  • Focus Therapeutic Use
  • Sponsors Thrombotargets Corporation
  • Most Recent Events

    • 03 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2014 Planned End Date changed from 1 Jul 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
    • 13 Dec 2013 Planned end date changed from 4 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top